Haloperidol Richter (Haloperidol)

Haloperidol Richter is indicated for the treatment of several acute and chronic psychiatric disorders.

• Schizophrenia, including maintenance therapy for stable patients.
• Acute psychotic episodes associated with schizophrenia or other mental health disorders.
• Manic episodes in bipolar disorder when rapid control of agitation is required.
• Severe agitation or aggression in patients with underlying psychotic conditions.

Side effects of haloperidol may vary in frequency and severity, ranging from mild to potentially serious.

Common

• Drowsiness or sedation, which may affect daily activities.
• Extrapyramidal symptoms such as tremor, rigidity, or restlessness (akathisia).
• Dry mouth, leading to discomfort or dental issues.

Serious

• Tardive dyskinesia, a potentially irreversible movement disorder that can persist after discontinuation.
• Neuroleptic malignant syndrome, characterized by fever, severe muscle rigidity, autonomic instability, and altered mental status.
• Cardiac arrhythmias, including QT interval prolongation that may increase the risk of ventricular tachycardia.

When prescribing Haloperidol Richter, clinicians should consider several precautionary measures to minimize risks.

• Review patient history for cardiovascular disease, seizure disorders, or hepatic impairment.
• Monitor for early signs of extrapyramidal symptoms, especially after dose changes.
• Use caution in elderly patients, who may be more susceptible to sedation, falls, and orthostatic hypotension.
• Evaluate pregnancy and lactation status; haloperidol is generally avoided unless benefits outweigh potential risks.
• Assess concomitant medications that may prolong the QT interval.
• Adjust dosing in patients with renal or hepatic dysfunction as recommended by clinical guidelines.

Haloperidol can interact with other drugs, affecting its efficacy or safety profile.

Avoid

• Other dopamine antagonists or high‑potency antipsychotics, which may increase the risk of extrapyramidal side effects.
• Medications that significantly prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics, fluoroquinolones).
• Strong CYP3A4 inhibitors such as ketoconazole or itraconazole, which can raise haloperidol plasma concentrations.

Use with caution

• CYP3A4 inducers like carbamazepine or phenytoin, which may reduce haloperidol levels and effectiveness.
• Central nervous system depressants (e.g., benzodiazepines, opioids) that can enhance sedation and respiratory depression.
• Anticholinergic agents that may mask early extrapyramidal symptoms, delaying detection.